Evidence map›Paper›PMID 32340264›Full record

ReviewInternational journal of molecular sciences2020

Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders-An Introduction to the OBERON Project.

Karine Audouze, Denis Sarigiannis, Paloma Alonso-Magdalena, Celine Brochot, Maribel Casas, Martine Vrijheid, Patrick J Babin, Spyros Karakitsios, Xavier Coumoul, Robert Barouki

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Endocrine disruptors in plastics alter β-cell physiology and increase the risk of diabetes mellitus.American journal of physiology. Endocrinology and metabolism · 2023
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Karine AudouzeInserm UMR S-1124, Université de Paris, 75006 Paris, France.
Denis SarigiannisHERACLES Research Center on the Exposome and Health, Aristotle University of Thessaloniki, Center for Interdisciplinary Research and Innovation, 57001 Thessaloniki, Greece.
Paloma Alonso-MagdalenaInstituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández, 03202 Elche, Spain.
Celine BrochotInstitut National de l'Environnement Industriel et des Risques (INERIS), Unité Modèles pour l'Ecotoxicologie et la Toxicologie (METO), Parc ALATA BP2, 60550 Verneuil en Halatte, France.
Maribel CasasISGlobal, 08003 Barcelona, Spain.
Martine VrijheidISGlobal, 08003 Barcelona, Spain.
Patrick J BabinDepartment of Life and Health Sciences, University of Bordeaux, INSERM U1211, MRGM, F-33615 Pessac, France.
Spyros KarakitsiosEnve.X, 55133 Thessaloniki, Greece.
Xavier CoumoulInserm UMR S-1124, Université de Paris, 75006 Paris, France.ORCID 0000-0003-2928-9648
Robert BaroukiInserm UMR S-1124, Université de Paris, 75006 Paris, France.
Inserm · FRUniversitat Pompeu Fabra · ESAristotle University of Thessaloniki · GRHôpital Necker-Enfants Malades · FRInstitut national de l'environnement industriel et des risques · FRUniversitat de Miguel Hernández d'Elx · ESUniversité de Bordeaux · FR

Funding

Horizon 2020 Framework Programme 825712
6 · The paper itself

Abstract

Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union (EU) to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed. The OBERON project will build an integrated testing strategy (ITS) to detect ED-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA). OBERON will combine (1) experimental methods (in vitro, e.g., using 2D and 3D human-derived cells and tissues, and in vivo, i.e., using zebrafish at different stages), (2) high throughput omics technologies, (3) epidemiology and human biomonitoring studies and (4) advanced computational models (in silico and systems biology) on functional endpoints related to metabolism. Such interdisciplinary framework will help in deciphering EDs based on a mechanistic understanding of toxicity by providing and making available more effective alternative test methods relevant for human health that are in line with regulatory needs. Data generated in OBERON will also allow the development of novel adverse outcome pathways (AOPs). The assays will be pre-validated in order to select the test systems that will show acceptable performance in terms of relevance for the second step of the validation process, i.e., the inter-laboratory validation as ring tests. Therefore, the aim of the OBERON project is to support the organization for economic co-operation and development (OECD) conceptual framework for testing and assessment of single and/or mixture of EDs by developing specific assays not covered by the current tests, and to propose an IATA for ED-related metabolic disorder detection, which will be submitted to the Joint Research Center (JRC) and OECD community.

Indexed as

Regional Medical ProgramsAnimalsBiological AssayBiomarkersComputational BiologyDisease SusceptibilityEndocrine DisruptorsEuropeHumansMetabolic DiseasesRisk AssessmentSystems BiologyBiomarkersEndocrine Disruptorsadverse outcome pathwayscomputational systems toxicologyendocrine disruptorsintegrative approachmetabolic disordersmetabolismnon-alcoholic fatty liver diseasesnon-animal testingobesitypredictive toxicology

Identifiers

PMID32340264
PMCPMC7216143
OpenAlexW3019074881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.